Rubicon Research’s arm enters into definitive agreement with GEn1E Lifesciences Inc

23 Oct 2025 Evaluate

Rubicon Research’s subsidiary -- Advagen Holdings Inc. (Advagen) has entered into a definitive agreement with GEn1E Lifesciences Inc. (Gen1E), to acquire Series Prime Preferred Stock in tranches, for a total consideration of up to $3 million. Series Prime Preferred Stock, convertible into around 2.2% of Gen1E’s common stock ownership subject to achievement of all milestones.

Gen1E is a pharmaceutical company with a pipeline of product candidates under development. GEn1E is based in Palo Alto, California, with a laboratory in Mountain View, California, USA.

Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of speciality products and drug-device combination products targeting regulated markets and in particular the United States.

Rubicon Research Share Price

635.70 11.70 (1.88%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Wework India Managem 595.85
Rubicon Research 635.70
Aegis Vopak Terminal 259.65
Mallcom 1170.85
Inducto Steel 47.59
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×